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Abstract
Instrumental variables (IV) are a useful tool for estimating causal effects in the presence
of unmeasured confounding. IV methods are well developed for uncensored outcomes, par-
ticularly for structural linear equation models, where simple two-stage estimation schemes
are available. The extension of these methods to survival settings is challenging, partly
because of the nonlinearity of the popular survival regression models and partly because of
the complications associated with right censoring or other survival features. We develop a
simple causal hazard ratio estimator in a proportional hazards model with right censored
data. The method exploits a special characterization of IV which enables the use of an
intuitive inverse weighting scheme that is generally applicable to more complex survival
settings with left truncation, competing risks, or recurrent events. We rigorously estab-
lish the asymptotic properties of the estimators, and provide plug-in variance estimators.
The proposed method can be implemented in standard software, and is evaluated through
extensive simulation studies. We apply the proposed IV method to a data set from the
Prostate, Lung, Colorectal and Ovarian cancer screening trial to delineate the causal effect
of flexible sigmoidoscopy screening on colorectal cancer survival which may be confounded
by informative noncompliance with the assigned screening regimen.
keywords: Causal treatment effect; Cox proportional hazards model; Instrumental variable
(IV); Noncompliance.
1 Introduction
Research studies are often fundamentally interested in understanding the causal effect of a treat-
ment or exposure on an outcome of interest (Holland, 1986). In observational studies, unmeasured
confounding is a major obstacle to estimating the causal effect of a nonrandomized exposure on
disease etiology. Such a challenge also arises in well-designed randomized clinical trials. When
there are issues of non-compliance in the treatment arms, the treatment decision may be based
on latent (unobserved) factors that strongly correlate with clinical outcomes. This would result
+The first two authors have equal contributions to this work∗Corresponding author: lpeng@emory.edu
1
ar
X
iv
:1
90
1.
11
05
0v
1 
 [s
tat
.M
E]
  3
0 J
an
 20
19
in bias from unmeasured confounding and hence complicate the task of estimating the “efficacy”
of the treatment.
Instrumental variables (IVs) offer a useful tool for estimating causal treatment or exposure
effects in these settings (Angrist and Imbens, 1995; Angrist et al., 1996; Loeys and Goetghebeur,
2003; Li and Lu, 2015; Li and Gray, 2016; MacKenzie et al., 2016). Informally, IVs have the char-
acteristics of being independent of unmeasured confounders, being related to the treatment, and
only being related to the outcome through the treatment (Baiocchi et al., 2014). In observational
studies, there are a variety of potential sources for instruments that can aid in the estimation
of causal effects, either of treatment or exposure (Baiocchi et al., 2014). In randomized clinical
trials with non-compliance, the treatment assignment mechanism can serve as an instrumental
variable.
The motivating example of this work is the Prostate, Lung, Colorectal and Ovarian (PLCO)
Cancer screening trial, which is a multi-center randomized trial designed to evaluate the effec-
tiveness of the screening with flexible sigmoidoscopy compared versus usual care. In this study,
77,449 subjects were randomly assigned to the intervention group, but only 85% complied with
the assigned sigmoidoscopy protocol. Such non-compliance may be outcome-related. For exam-
ple, relatively healthy individuals may be more likely to skip the screening. In the presence of
unmeasured confounding, neither intent-to-treat (ITT) analysis nor “as-treated” analysis would
be adequate for assessing the causal benefit of the treatment (i.e. flexible sigmoidoscopy screen-
ing). A possible remedy is an IV analysis that properly adjusts for the selection bias induced by
subjects’ post-randomization care selection. The assigned treatment in a randomized trial serves
a natural instrumental variable which may be utilized in this analysis.
IV methodology has primarily focused on linear models and continuous outcomes in contexts
without censoring. Recently, research on IV methodology for time-to-event data with right
censoring has grown rapidly. For example, Baker (1998) developed an IV method for randomized
trials with all-or-none compliance and discrete-time survival data by estimating the hazards for
compliers under treatment and control in a manner analogous to two-stages least squares (TSLS)
methods for linear models. Baiocchi et al. (2014) gave a brief summary of this method in their
review of IV methods. Building on Baker (1998)’s work, Nie et al. (2011) developed an estimation
method with improved efficiency.
Robins and Tsiatis (1991) considered a structural accelerated failure time model and devel-
oped estimators for the causal treatment effect in the context with non-compliance and only
administrative censoring. Joffe (2001) provided a detailed discussion of this general approach.
Imposing parametric distributional assumptions, Li and Lu (2015) developed a Bayesian ap-
proach for IV analysis with censored time-to-event outcome under a two-stage linear model. Li
et al. (2015) and Tchetgen et al. (2015) developed IV based methods under additive hazards
modeling of time-to-event data. Specifically, Li et al. (2015) proposed a two-stage, consistent
estimation procedure for a causal treatment effect by substituting the predicted treatment from
the observed covariates and IV. Tchetgen et al. (2015) developed a “control function” approach,
where the residual from a model with the treatment as the outcome was added to the additive
hazards regression model. More recently, Martinussen et al. (2016) studied structural cumulative
survival models with time-varying exposures in a specification that was related to the additive
hazards model.
In time-to-event analysis, proportional hazards model is the most popular formulation for
the effects of treatment and covariates. There have been several IV approaches developed under
the proportional hazards modeling. For example, for the special case of all or none noncompli-
ance without covariates, Loeys and Goetghebeur (2003) proposed an estimate for the complier
proportional hazards effect of treatment by deriving a properly imputed partial likelihood that
recovered the unobserved information on the treatable subgroup in the control arm. Also working
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in the noncompliance setting, Cuzick et al. (2007) constructed a Mantel-Haenszel-type estimator
for the case without covariates and a partial-likelihood based estimator when covariates were
present and independent of compliance types. A full likelihood based approach was explored for
situations where covariates were correlated with compliance type. Li and Gray (2016) further
proposed an EM algorithm for the full likelihood based estimation. Yu et al. (2015) tackled the
problem of estimating causal estimands including the complier average causal effect, complier
survival probability, and complier quantile causal effect under the semiparametric transformation
model. They adapted the nonparametric likelihood estimation technique of Zeng and Lin (2007),
and provided an EM algorithm for implementing the proposed estimation as well as theoretical
justifications. While the likelihood-based strategies accommodate both censoring and covariates
in the estimation of the causal treatment effect with censored time-to-event data, the resulting
estimation and inference procedures are generally very complicated. The computational com-
plexity and stability may become unbearable when the sample size is large, such as in the PLCO
Cancer screening trial. Furthermore, they require specifying causal models for all latent com-
pliance classes, not just that of interest, which may impair the robustness of these methods to
potential model misspecification.
In this work, we develop a new IV approach to estimating a causal treatment effect under the
proportional hazards modeling of time-to-event outcome subject to independent right censoring.
The causal estimand is defined within the latent subgroup of compliers as in most existing work
on causal proportional hazards regression. However, our method does not need to impose re-
gression models for the latent compliance classes other than the complier subgroup. Our key
strategy is to adapt the seminal work of Abadie (2003) which provides a simple link between
the unconditional moment of the observed data and the conditional moment given the latent
complier group. Abadie (2003) developed a simple weighting strategy which is easily applied to
estimating equations which are sums of independent terms. However, an analogous application
to the proportional hazards regression is not straightforward. This is because the partial likeli-
hood does not yield an estimating function of the simple form as a sum of independent terms, as
with the least squares criterion for linear regression. To circumvent this difficulty, we take care-
fully designed steps to incorporate the weighting idea of Abadie (2003) through the asymptotic
influence functions of the partial likelihood score equation. We establish the large sample prop-
erties of the resulting parameter estimators, including consistency and asymptotic normality. To
attain stable and fast computation, we make further efforts to devise computational algorithms
to obtain the proposed parameter estimators. The calculations can be easily implemented via
existing software for weighted proportional hazards regression. We also illustrate that the pro-
posed weighting scheme is generally applicable to more complex survival settings, for example, in
the presence of left truncation, competing risks, or recurrent events. Such a broad applicability
appears lacking in existing IV approaches for proportional hazards models.
In Section 2, we first introduce the potential outcomes framework including the latent com-
pliance groups, the IV assumptions, and the set-up of causal proportional hazards regression. We
next describe the proposed estimation procedure with randomly censored data, discuss compu-
tational considerations, and present a modification of the proposed method which has improved
computational features. Adaptations to settings with left truncation, competing risks, or recur-
rent events are also discussed. We rigorously present the consistency and asymptotic normality
of the estimators. The results include a closed form for the asymptotic variance of the estimator
and a consistent plug-in variance estimator. Bootstrap variance estimates are also provided.
The results from extensive simulations are reported Section 3 and demonstrate that the methods
perform well with realistic sample sizes. In Section 4, we apply our methods to the data from
the PLCO Cancer screening trial. Some remarks conclude in Section 5.
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2 Weighted Partial Likelihood Estimation for Causal Pro-
portional Hazards Models
2.1 Potential Outcomes Framework
We introduce the potential outcomes framework and notation commonly employed in the causal
inference literature. Consider potential survival times T1 and T0 based on receiving (D = 1)
and not receiving the treatment (D = 0), respectively. Define V as a binary IV, and define the
potential treatment Dv such that D1 denotes the treatment received when V = 1 and D0 denotes
the treatment received when V = 0. Following the terminology of Abadie (2003), subjects can be
classified into 4 latent compliance groups based on the potential treatment indicators: compliers
(D1 > D0), always-takers (D1 = D0 = 1), never-takers (D1 = D0 = 0), and defiers (D1 < D0). In
the PLCO Cancer screening trial, compliers would be the individuals who were assigned to the
intervention group and also took the flexible sigmoidoscopy screening. Always-takers (or never-
takers) are defined as always (or never) taking the flexible sigmoidoscopy screening. Defiers are
individuals who would take the the flexible sigmoidoscopy screening if assigned to the usual care
group but not if assigned to the intervention group. Since D1 and D0 cannot be observed at the
same time, we are not able determine the latent compliance group membership of any individual
based on the observed data alone.
Define the potential outcome for each subject as Tvd, which represents the survival time T
if V = v and D = d. Let X represent the covariate vector. We re-state several key assumptions
from Abadie (2003) about the IV, V :
Assumptions (A1)-(A4). Let Tvd,X, V,D,Dv be defined as above.
(A1) Independence of the instrument:
(T00, T01, T10, T11,D0,D1) ⊥ V ∣X
(A2) Exclusion of the instrument: P (T1d = T0d∣X) = 1 for d = 0,1.
(A3) First stage: 0 < P (V = 1∣X) < 1 and P (D1 = 1∣X) > P (D0 = 1∣X)
(A4) Monotonicity: P (D1 ≥D0∣X) = 1
Assumption (A1) says that the instrument V is as good as random conditional on the co-
variates X, or equivalently, that V is independent of unmeasured confounders conditional on X.
Assumption (A2) says that the instrument V only influences the outcome T through its effect
on the treatment D. Assumption (A3) states that every subject has some chance of receiving
the instrument V , conditional on the covariate X, and that conditional on X, V has an effect
on the treatment received. Finally, assumption (A4) says that with probability one, defiers do
not exist.
2.2 Model Formulation
Our focus is to estimate and make inferences about the treatment effect for the latent group of
compliers. Specifically, we adopt Cox’s proportional hazards regression model to formulate the
effects of treatment and covariates for compliers:
h(t;D,X) = h0(t) exp{βdD +βTxX}, (1)
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where h(t;D,X) is the hazard function for compliers defined as
h(t;D,X) = lim
∆t→0 Pr(t ≤ T ≤ t +∆t∣T ≥ t,D1 >D0,D,X)∆t ,
and h0(t) is an unspecified baseline hazard at time t. In model (1), βd is the causal estimand of
the primary interest, which can be interpreted as the causal treatment effect for compliers after
adjusting for the covariate effects captured by βx (Abadie, 2003). Such a quantity has frequently
been of interest in literature (Loeys and Goetghebeur, 2003; Cuzick et al., 2007; Yu et al., 2015,
for example). It is worth emphasizing that the proportional hazards model (1) is only assumed
for compliers. In contrast, likelihood-based approaches (Cuzick et al., 2007; Yu et al., 2015; Li
and Gray, 2016, for example) typically require distributional modeling for the other compliance
subgroups (e.g. always takers, never-takers) and may be biased under misspecification of those
models.
2.3 Estimation
In practice, T is often subject to right censoring by C; thus we observe W = min(T,C) and
δ = I(T ≤ C) instead of T . We adopt the standard random censoring assumptions that C is
independent of T conditional on (V,D,X). We further assume that C is independent of V
given X. Defined O = (W,δ,D,X, V ). The observed data consist of n independently identically
distributed (i.i.d.) replicates of O, denoted by {Oi}ni=1 = {(Wi, δi,Di,Xi, Vi)}ni=1. Define Yi(t) =
I(Wi ≥ t) and Ni(t) = I(Wi ≤ t, δi = 1), which represent the at-risk process and the observed
event counting process for subject i respectively. We also assume that there are no ties (i.e.
dNi(t) ≤ 1). In the sequel, we use the subscript i to differentiate population quantities and their
sample analogues throughout the paper.
Let β0 = (βd,βx) and Z = (D,X). When all subjects are known to be compliers, the
estimation of β0 can proceed through standard Cox regression analysis (Andersen and Gill,
1982). This is because, in this case, the hazard function for the whole study population,
λ(t∣Z) ≡ lim∆t→0 Pr(t ≤ T ≤ t +∆t∣T ≥ t,D,X)/∆t, equals that for the latent complier subgroup,
exp(βTZ) h0(t). Then M(t) ≡ N(t) − ∫ t0 Y (s) exp(βT0 Z)h0(s)ds is a martingale, and thus a
consistent estimator of β0 can be obtained as the solution of the partial likelihood score equation,
Un(β) = 1√
n
n∑
i=1∫ ∞0
⎧⎪⎪⎨⎪⎪⎩Zi − S
(1)
n (β, s)
S
(0)
n (β, s)
⎫⎪⎪⎬⎪⎪⎭ dNi(s), (2)
where S
(j)
n (β, s) = ∑nl=1 Yl(s)Z⊗jl eβTZl for j = 0,1,2. Here and in the sequel, for a vector v,
v⊗0 = 1, v⊗1 = v, and v⊗2 = vvT .
Next we consider the more realistic case where the study population consists of both compliers
and non-compliers. In this case, λ(t∣Z) generally deviates from the hazard function assumed for
the complier group, h0(t) exp(βT0 Z). As a result, M(t) is no longer a martingale for the whole
study population, and equation (2) would fail to provide a valid estimate for β0.
To construct an appropriate estimating equation for β0, we utilize the fact that M(t) remains
a martingale for the complier group. Using this fact, we can show that µc(β0) = 0 under model
(1), where s
(j)
c (β, s) = E(Y (s)Z⊗jeβTZ∣D1 >D0) (j = 0,1,2) and
µc(β) = E ⎡⎢⎢⎢⎢⎣∫
∞
0
⎧⎪⎪⎨⎪⎪⎩Z − s
(1)
c (β, s)
s
(0)
c (β, s)
⎫⎪⎪⎬⎪⎪⎭dM(s)∣D1 >D0
⎤⎥⎥⎥⎥⎦ .
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However, µc(β) cannot be directly used to estimate β0 because the latent complier group,{D1 > D0}, is not observed. To tackle this difficulty, we adopt the strategy of Abadie (2003),
which established a simple link between the unconditional moment of the observed data and
the conditional moment of the data within the complier group. A simple weighting approach
may be employed to identify the regression parameters associated with the complier group. More
specifically, let g(⋅) be a measurable real function of (T,D,X,C) such that E∣g(T,D,X,C)∣ <∞.
Under assumptions (A1)–(A4) and given C is independent of V given X, Theorem 3.1 of Abadie
(2003) implies that
E{g(T,D,X,C)∣D1 >D0} = 1
Pr(D1 >D0)E{κ ⋅ g(T,D,X,C)} (3)
where
κ = 1 − D(1 − V )
Pr(V = 0∣X) − (1 −D)VPr(V = 1∣X) . (4)
This result suggests that a weighting scheme involving κ can lead to the identification of moment-
type statistics for compliers. One should recognize that κ can take both positive and negative
values. This differs from standard weighting procedures based on probability weighting, where
the weights are always positive as a result of probabilities being nonnegative. This creates
nonstandard computational challenges, which are discussed further below.
Using (3), we obtain the following key results for deriving an estimating equation for β0:
µc(β) = 1Pr(D1 >D0)E
⎡⎢⎢⎢⎢⎣κ∫
∞
0
⎧⎪⎪⎨⎪⎪⎩Z − s
(1)
c (β, s)
s
(0)
c (β, s)
⎫⎪⎪⎬⎪⎪⎭dM(s)
⎤⎥⎥⎥⎥⎦ ,
where
s(j)c (β, s) = E(κY (s)Z⊗jeβTZ)Pr(D1 >D0) , j = 0,1,2.
Suppose κi is known for each subject i. One may construct a weighted estimating equation
for β0, Un,κ(β) = 0, where
Un,κ(β) = 1√
n
n∑
i=1∫ ∞0 κi ⎛⎝Zi −
⎧⎪⎪⎨⎪⎪⎩S
(1)
n,κ(β, s)
S
(0)
n,κ(β, s)
⎫⎪⎪⎬⎪⎪⎭⎞⎠ dNi(s)
with S
(j)
n,κ(β, s) = ∑nl=1 κlYl(s)Z⊗jl eβTZl . Note that Un,κ(β) remains the same if dNi(s) is re-
placed by dMi(s), and hence Un,κ(β) is proportional to an empirical counterpart of µc(β). This
justifies the use of Un,κ(β) for constructing the estimating equation for β0.
In general, κi’s is known a priori, for example, with external information. In practice, we
propose to estimate κi by imposing additional modeling assumptions for Pr(V = 1∣X). Specially,
we may assume a logistic regression model for V :
P (V = 1∣X) ≡ ψ(α0,X) = exp(α01 +αT02X)
1 + exp(α01 +αT02X) , (5)
with α0 = (α01,αT02)T . Let αˆ be the maximum likelihood estimator of α0 (Gourieroux and
Monfort, 1981; Agresti, 2013) and define
κˆi = 1 − Di(1 − Vi)
1 − ψ(αˆ,Xi) − (1 −Di)Viψ(αˆ,Xi) . (6)
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Replacing the κi in Un,κ(β) by κˆi leads to the proposed estimating equation:
Un,κˆ(β) = 0, (7)
where
Un,κˆ(β) = 1√
n
n∑
i=1∫ ∞0 κˆi ⎛⎝Zi −
⎧⎪⎪⎨⎪⎪⎩
S
(1)
n,κˆ(β, s)
S
(0)
n,κˆ(β, s)
⎫⎪⎪⎬⎪⎪⎭⎞⎠ dNi(s). (8)
Denote the solution to equation (7) by βˆ. The detailed computational algorithm for obtaining
βˆ, and the related algorithmic issues and remedies are discussed in the next subsection.
2.4 The Computational Algorithm
The form of the proposed estimation equation (7) closely resembles the estimating equation for
a weighted Cox proportional hazards regression. However, an important distinction is that κˆi’s
in (7) can take negative values. As a result, Un,κˆ(β) can have a highly irregular surface with
multiple zero-crossings. To address this complication, we propose to locate βˆ through finding
the maximizer of a properly designed objective function. Specifically, instead of directly solving
Un,κˆ(β) = 0, we propose to obtain βˆ as the maximizer of the following objective function
C¯n,κˆ(β) = 1
n
n∑
i=1 κˆiδi [βTZi − log{S˜(0)n,κˆ(β,Wi)}] , (9)
where S˜
(0)
n,κˆ(β, t) = max(S(0)n,κˆ(β, t), ν) and ν is a pre-specified small positive value. The justifica-
tion for doing so is that ∂C¯n,κˆ(β)/∂βT would be nearly the same as n−1/2Un,κˆ(β) because ν can
be arbitrarily small. Truncating S
(0)
n,κˆ(β, t) below by ν ensures the positiveness of the resulting
quantity. In theory, the asymptotic limit of S
(0)
n,κˆ(β, t) is strictly positive under mild regular-
ity conditions. Therefore, such a truncation should have negligible impact on the finite-sample
performance of βˆ when n is reasonably large. In our numerical studies, we choose ν = 10−4.
The procedure for obtaining βˆ is as follows.
1. Fit the logistic regression model (5) to {(Vi,Xi)}ni=1 and obtain αˆ.
2. Calculate κˆi using formula (6).
3. Find the maximizer of the objective function C¯n,κˆ(β) in (9) by an optimization routine,
such as optim() function in R (R Core Team, 2017).
2.5 A Modified Weighting Scheme
In principle, the objective function C¯n,κˆ(β) approaches a limit that is concave, and standard
optimization routines are expected to work well when the sample size is large. However, the
presence of negative weights κi’s can sometimes lead to a highly irregular surface for C¯n,κˆ(β)
and Un,κˆ(β) (see figures in Appendix C) and result in numerical instability for estimating β0. To
address this problem, we propose a modified weighting scheme, which can avoid negative weights
and allow us to obtain βˆ through standard computational routines for the weighted proportional
hazards regression, such as the coxph() function in R (Therneau, 2015).
Let U = (W,δ,D,X). We define a modified weight by projecting the original weight κ as
follows:
κv = E(κ∣U) = 1 − D(1 − v0(U))
P (V = 0∣X) − (1 −D)v0(U)P (V = 1∣X) , (10)
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where v0(U) = E(V ∣U) = P (V = 1∣W,δ,D,X). Adapting the arguments of Abadie et al. (2002),
we can show that κv = P (D1 > D0∣U) and κv can play the same role as κ in equation (3) (see
Appendix A). This result indicates that κv is a probability; thus it is always non-negative and
can be regarded as a proper weight. Adopting the weighting scheme by κv can avoid the potential
numerical issues present with κ. We propose to estimate κv as follows.
1. Stratify the data by the censoring and treatment status: {(δ = c,D = d)}, c = 0,1, d = 0,1.
2. Within each stratum, fit a nonparametric or parametric regression model for V given
covariates (W,X). This will provide an estimate for v0(U), denoted by vˆ(U).
3. Calculate the estimated κv as
κˆv = 1 − D(1 − vˆ(U))
1 − ψ(αˆ,Xi) − (1 −D)vˆ(U)ψ(αˆ,Xi) .
In Step 2 above, we may consider non-parametric power series (NPPS) regression or logistic
regression for V given (W,X). Based on our extensive numerical experiences (including those
reported and not reported in Section 3), a second-order logistic regression model with the inter-
action between W and X works well compared to approaches that estimate κˆv from NPPS, or
the first-order logistic regression. Note that, with finite sample sizes, the resulting estimator κˆv
may be negative or greater than 1. To circumvent the undesirable numerical properties associ-
ated with negative weights, we propose a slightly different modified weight, κˆv,tr, that truncates
κˆv such that its value lies strictly in an interval I ⊂ (0,1), say [0.01,0.99]. Since the true weight
κv is between 0 and 1 and we can let I be arbitrarily close to (0,1), there should be negligible
asymptotic bias induced by such a truncation. Using κˆv,tr in place of κ in (7), we can easily ob-
tain βˆ through the R function, coxph(), with the weight argument properly specified. In Section
3, we thoroughly examine the performance of βˆ with different choices of weight.
2.6 Generalizations to complex survival settings
Survival data are often subject to complications other than random right censoring, for example,
left truncation, competing risks, and recurrent events. The proposed weighting scheme can be
readily adapted to accommodate these additional data complexities.
Left truncation: Suppose the survival time T is subject to left truncation by L. We observe
O˜ ≡ (W˜ , δ˜, L˜, D˜, X˜, V˜ ), where O˜ follows the conditional distribution of (W,δ,L,D,X,V ) given
L < W . Let O˜i ≡ (W˜i, δ˜i, L˜i, D˜i, X˜i, V˜i) be the sample analogue of O˜. Assume that (L,C) is
independent of T given (V,D,X), and (L,C) is independent of V given X.
Define N˜(t) = I(L˜ < W˜ ≤ t, δ = 1), Y˜ (t) = I(W˜ ≥ t > L˜), and M˜(t) ≡ N˜(t) −∫ t0 Y˜ (s) exp(βT0 Z)h0(s)ds. The partial likelihood score equation under left truncation (Andersen
et al., 2012) suggests that µ˜c(β0) = 0, where
µ˜c(β) = E ⎡⎢⎢⎢⎢⎣∫
∞
0
⎧⎪⎪⎨⎪⎪⎩Z˜ − s˜
(1)
c (β, s)
s˜
(0)
c (β, s)
⎫⎪⎪⎬⎪⎪⎭dM˜(s)∣D1 >D0, L <W
⎤⎥⎥⎥⎥⎦ ,
where s˜(j)c (β, s) = E(Y˜ (s)Z˜⊗jeβT Z˜∣D1 > D0, L < W ) (j = 0,1,2). Applying the same technique
shown in (3), one can establish that
µ˜c(β) = 1Pr(D1 >D0∣L <W )E
⎡⎢⎢⎢⎢⎣κ˜∫
∞
0
⎧⎪⎪⎨⎪⎪⎩Z˜ − s˜
(1)
c (β, s)
s˜
(0)
c (β, s)
⎫⎪⎪⎬⎪⎪⎭dM˜(s)∣L <W
⎤⎥⎥⎥⎥⎦ , (11)
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where
κ˜ = 1 − D˜(1 − V˜ )
Pr(V˜ = 0∣X˜, L <W ) − (1 − D˜)V˜Pr(V˜ = 1∣X˜, L <W )
and
s(j)c (β, s) = E(κlY˜ (s)Z˜⊗jeβT Z˜∣L <W )Pr(D1 >D0, L <W ) , j = 0,1,2.
The result in (11) suggests a simple adaptation of the proposed method to the case with
random left truncation, where the main modification is to replace Zi, Yi(t), Ni(t) in Un,κ(β)
by Z˜i, Y˜i(t), N˜i(t) respectively. The weights κˆ or κˆv can be calculated in the same way as in
Section 2.3 and 2.5 based on D˜i, V˜i, X˜i, W˜i observed under left truncation.
Competing risks: Consider a typical competing risks setting with K types of competing
failures. Let T = min(T1, . . . , TK), where Tk denotes the latent event time to failure type k
(k = 1, . . . ,K). Let C denote time to random censoring for T , which satisfies the same censoring
assumptions stated in Section 2.3. Let W = min(T,C) and define η as 0 if T > C and the type
of failure otherwise. We observe (T, η, V,D,X).
When the interest lies in the minimal event time T , one can simply apply the procedures in
Section 2.3-2.5 to the observed data on (T, I(η ≠ 0), V,D,X). This is appropriate because T ,
when treated as a survival outcome of interest, is only subject to random censoring by C, and
I(η ≠ 0) indicates whether T is observed or not.
When the interest pertains to a specific type of failure, say type k, we propose to consider
the following variant of model (1) to define the causal treatment effect of interest:
hk(t;D,X) = hk,0(t) exp{βd,kD +βTx,kX}, (12)
where hk(t;D,X) is the type-k cause-specific hazard function for compliers defined as
hk(t;D,X) = lim
∆t→0 Pr(t ≤ T ≤ t +∆t∣T ≥ t, δ = k,D1 >D0,D,X)∆t ,
and hk,0(t) is an unspecified baseline cause-specific hazard at time t for type k. Under model
(12), βd,k represents the causal treatment effect on the type-k cause-specific hazard for compliers
after adjusting for covariates in X. When all subjects are compliers, one can estimate model (12)
using a slightly modified partial likelihood score equation, which is (2) with I(η = k) replacing
δ (Kalbfleisch and Prentice, 2011). Following the same arguments for justifying the weighting
technique presented in Section 2.3, we can show that incorporating κˆ or κˆv into this modified
score equation yields an unbiased estimating equation for βx,k. In other words, naively treating
the competing risks for type-k failure as independent censoring events and applying the proposed
IV method for randomly censored data lead to legitimate estimation and inference for the causal
treatment effect on the type-k cause-specific hazard.
Recurrent events: In survival settings, the event of interest may occur repeatedly over
time. The proportional hazards model can be naturally extended to a proportional intensity
model to accommodate recurrent events (Andersen and Gill, 1982). Let T (j) denote the j-th
recurrent event. Define N∗(t) = ∑∞j=1 I(T (j) ≤ t) and Nr(t) = ∑∞j=1 I(L < T (j) ≤ R), which
respectively represent the underlying and the observed counting processes of recurrent events.
Here (L,R] denotes the time window in which recurrent events are observed. We assume L and
R are independent of V given X and are independent of T (j)’s conditional on (V,D,X). Let
Y r(t) = I(L < t ≤ R), which denotes the at-risk process. A causal proportional intensity model
is defined similarly to the Cox’s proportional hazards model (1):
λ(t) = λ0(t) exp{βr,dD +βTr,xX}, (13)
9
where λ(t) denotes the intensity function associated with N∗(⋅) given compliers (i.e. D1 > D0),
and λ0(t) is an unspecified baseline intensity function. The causal treatment effect on the
recurrent events for compliers is captured by βr,d. As shown by Andersen and Gill (1982), in
the setting where all subjects are compliers, βr,d can be estimated by equation (2) with N
r(⋅) in
place of N(⋅) and Y r(⋅) in place of Y (⋅). Adapting the weighting technique developed in Section
2.3 and 2.5, we can similarly modify the estimating equation for βr,d by incorporating weights
κˆ or κˆv. That is, we can obtain an unbiased estimate for βr,d by solving the equation (7) with
Nr(⋅) and Y r(⋅) in place of N(⋅) and Y (⋅).
2.7 Large Sample Results
To ease presentation, we first introduce some new notation. Define
U¯n,κ(β) = 1√
n
n∑
i=1∫ ∞0 κi
⎡⎢⎢⎢⎢⎣Zi −
⎧⎪⎪⎨⎪⎪⎩s
(1)
c (β, s)
s
(0)
c (β, s)
⎫⎪⎪⎬⎪⎪⎭
⎤⎥⎥⎥⎥⎦ dMi(s),
En,κ(β, t) = S(1)n,κ(β,t)
S
(0)
n,κ(β,t) , En,κˆ(β, t) = S(1)n,κˆ(β,t)S(0)n,κˆ(β,t) , ec(β, t) = s(1)c (β,t)s(0)c (β,t) , V n,κ(β, t) = S(2)n,κ(β,t)S(0)n,κ(β,t) −
En,κ(β, t)⊗2, V n,κˆ(β, t) = S(2)n,κˆ(β,t)
S
(0)
n,κˆ
(β,t) − En,κˆ(β, t)⊗2, and vc(β, t) = s(2)c (β,t)s(0)c (β,t) − ec(β, t)⊗2. Let
Σ0 = ∫ ∞0 vc(β0, t)s(0)c (β0, t)h0(t)dt. We let ∥ ⋅ ∥ denote Euclidean norm.
We assume the following regularity conditions:
(C1): The parameter space for β, B, is compact.
(C2): ∥Z∥ <∞ and ∣κ∣ <∞.
(C3): s
(0)
c (β, t) is bounded away from 0 uniformly in β and t.
(C4): Σ0 > 0.
(C5): αˆ −α0 →a.s. 0.
(C6) There exists an influence function Iα(⋅) such that
∥n1/2(αˆ −α0) − n−1/2 n∑
i=1 Iα(α0,Oi)∥ = o(1), a.s.
We establish the consistency and the asymptotic normality for the proposed estimator in the
following theorems:
Theorem 1. (Consistency) Under conditions (C1)-(C5), βˆ →a.s. β0.
Theorem 2. (Asymptotic normality) Under conditions (C1)-(C6), n1/2(βˆ − β0) →d N(0,Ω),
where Ω is defined in Appendix B (see equation (24)).
The regularity conditions (C1)-(C2) impose the boundedness of the parameter space and co-
variates, which are mild and are often met in practice. The boundedness of κ is satisfied when
Pr(V = 0∣X) is always away from 0 and 1. Conditions (C3)-(C4) are standard assumptions for
Cox proportional hazard regression methods. For example, condition (C4) ensures the identi-
fiability of β0. Conditions (C5)-C(6) depict reasonable requirements on the estimator of α0,
such as consistency and i.i.d. sum representation. The detailed proofs of Theorems 1 and 2 are
provided in the Appendix B.
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2.8 Variance Estimation
In the proof of Theorem 2, we derive a closed form for the asymptotic variance of n1/2(βˆ−β0); see
equation (24) in the Appendix B. A consistent variance estimator for βˆ can be obtained by Ωˆ/n,
where Ωˆ is Ω with unknown quantities replaced by their empirical counterparts or consistent
estimators.
An alternative approach to estimating the asymptotic variance of βˆ is to use bootstrapping.
The detailed procedure follows:
1. Resample n observations from the original dataset with replacement, {Obi}ni=1, and add
some small amount of noise (e.g. N(0,10−10)) to avoid the presence of ties in the resampled
data.
2. Calculate βˆb based on {Obi}ni=1 with weights as described in Section 2 (i.e. κˆ, κˆv, or κˆv,tr).
3. Repeat steps 1-2 for b = 1, ...,B.
4. Estimate the asymptotic variance of βˆ by the empirical variance of {βˆb}Bb=1.
In the bootstrapping procedure, the computations in Step 2 may fail to converge. In such a
case, we would carry out Step 3 until there are B convergent estimates. In addition, repeated re-
sampling may occasionally produce outlier estimates that artificially inflate the empirical variance
in Step 4. When this occurs, one may estimate the standard deviation of βˆ by the median abso-
lute deviation, namely, 1.4826 ×MAD, where MAD = median(∣βˆb −median(βˆb)∣) (Rousseeuw
and Croux, 1993). This alternative approach performs quite well based on our numerical expe-
riences.
3 Simulation Study
We conduct extensive simulations to assess the performance of the proposed estimators. To
create data under assumptions (A1) to (A4), we take the following steps:
1. Generate X from some bounded distribution.
2. Generate the latent group membership (i.e. complier, always-taker or never-taker) from a
multinomial distribution.
3. Let P (V = 1∣X) = exp(α01+αT02X)
1+exp(α01+αT02X) , and then generate V ∼ Bernoulli(P (V = 1∣X)). Treat-
ment D is then automatically determined by V and latent group membership generated in
Step 2.
4. For compliers, generate potential survival times T00 = T10 = exp(−βTxX +) and T01 = T11 =
exp(−βTxX − βd + ), where  follows the extreme value distribution. The survival time
T is then determined by (V,D) (i.e. T = Tvd. It is easy to show that T follows the Cox
regression model (1).
5. For non-compliers, perform a similar process, where T00 = T10 and T01 = T11 and T is
determined by (V,D) (i.e. T = Tvd). The model used to generate T00 or T01 is not
restricted to the Cox regression model.
6. Draw independent censoring times C ∼ Exponential(0.5).
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Table 1: Cases considered for each scenario
Case P (D1 >D0) n X
1 1/3 1000 Uniform(-1, 1)
2 2/3 1000 Uniform(-1, 1)
3 1/3 4000 Uniform(-1, 1)
4 2/3 4000 Uniform(-1, 1)
5 1/3 1000 Bernoulli(0.5)
6 2/3 1000 Bernoulli(0.5)
7 1/3 4000 Bernoulli(0.5)
8 2/3 4000 Bernoulli(0.5)
We consider two basic data generation scenarios with a single covariate X. In scenario 1, for
compliers, survival times are generated with β0 = (βd, βx) = (−0.5,−0.2). Survival times for non-
compliers in scenario 1 are generated according to T = exp(−0.02X+1) where 1 ∼ N(0,0.01) (i.e.
no treatment effect). In scenario 2, compliers’ survival times are generated with β0 = (−0.3,0.05).
Non-compliers’ survival times are also generated from a Cox proportional hazards regression
model, where T = exp(0.5D − 0.05X + 2) and 2 follows the extreme value distribution.
For each scenario, X is simulated from either a Bernoulli(0.5) or Uniform(−1,1) distribu-
tion, and we vary the probability of compliers from 1/3 to 2/3 (with always-takers and never-
takers sharing the remaining probability equally). We also vary the sample size between n = 1000
and n = 4000. We fix logistic regression parameters (α01, α02) = (0,1). Table 1 summarizes the
8 cases run for each of the 2 scenarios.
We compare several different methods of estimation: (1) the benchmark estimate based only
on the compliers (unknown in a real data analysis); (2) the naive estimate which assumes the
entire sample follows the same Cox model; (3) the proposed κˆ-weighted estimate; (4) the modified
κˆv-weighted estimate; (5) the estimate based on the truncated modified weights κˆv,tr. Hereafter,
we refer to these methods as “Complier”, “κ”, “κv”, “κv,tr”.
To estimate κˆv and κˆv,tr, we estimate v0(U) = P (V = 1∣W,X,D, δ) using the method de-
scribed in Section 2.5 with a second-order logistic regression including the interaction between
W and X for each of the 4 partitions by the censoring and treatment status. Without further
mentioning, estimation using κˆ and κˆv follows the algorithms and caveats laid out in Section 2.4
and 2.5, where βˆ is estimated by maximizing the objective function in (9). More specifically, we
use the R function optim with the BFGS method option (R Core Team, 2017), considering three
different starting values (based on the naive estimate, ±0.5), to solve the maximization problem.
For the method κv,tr, we use the R function coxph to implement the proposed estimation as
described in Section 2.5. For each method under comparison, we check whether the resulting
estimate solves the proposed estimating equation within some tolerance (e.g. 0.05). We record
a failure to converge if such an estimate cannot be produced.
The top row of Figure 1 shows the convergence rates for the three proposed estimators. In
scenario 1, the convergence rates of both κˆ and κˆv are close to 100% times across the 8 cases
considered. In scenario 2, the convergence rate varies considerably, but generally increases with
n and the proportion of compliers P (D1 > D0). Anecdotal examination reveals that the ob-
jective and estimating function surfaces for this scenario can be highly irregular. In contrast,
as κˆv,tr-weights are always positive, the resultant surfaces are smooth and the resulting conver-
gence rates are always 100%. The second row of Figure 1 demonstrates the empirical bias by
comparing the treatment and covariate parameter estimates to the truth. The naive parameter
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Figure 1: Simulation results: convergence rates, mean estimates, and empirical coverage proba-
bilities of 95% confidence intervals: Complier (∎); Naive (●); κ (○); κv (+); κvtr (S)
estimators generally demonstrate large empirical bias, with the proposed methods reducing the
bias considerably.
In Figure 2, we compare various standard error (SE) estimates to the empirical standard
deviations (SD) of the proposed estimators. We denote the mean and median estimated SE
based on the analytic variance estimation by Mean SE and Median SE respectively, and denote
the mean and median estimated SE based on the bootstrapping variance estimation by Mean
Bootstrap SE and Median Bootstrap SE respectively. The empirical standard deviation (SD)
is denoted by Empirical. For the method κ, we evaluate both analytic variance estimation and
bootstrapping based variance estimation. It is observed that both Mean Bootstrap SE and
Median Bootstrap SE are rather close to the corresponding empirical SDs in both Scenarios 1
and 2. As for the analytic variance estimation, Median SE s are in good agreement with the
empirical SDs, while in Scenario 2, many Mean SE s considerably depart from the empirical SDs.
The latter phenomenon may reflect the unstable performance of the κ-weighted estimator in
Scenario 2, which is consistent with the lower convergence rates of the method κ in Scenario 2.
For the methods κv and κv,tr, we only examine the bootstrapping based variance estimation.
Two extreme outliers are removed from calculating the mean bootstrap SE for the covariate
coefficient estimate based on method κv in the Case 5 of Scenario 1. We observe fairly small
discrepancies among Mean Bootstrap SE s, Median Bootstrap SE s, and empirical SDs for both
Scenarios 1 and 2, while the method κv,tr shows slightly better performance.
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Figure 2: Simulation results: the estimated standard errors and empirical standard deviations of
κˆ, κˆv, κˆv,tr weighted estimators: Empirical (◻); Mean SE (+); Median SE (▽); Mean Bootstrap
SE (×); Median Bootstrap SE (S)
The bottom row of Figure 1 demonstrates the empirical coverage probabilities of 95% con-
fidence intervals, constructed as βˆ ± z0.975 × SˆE(βˆ), where SˆE(βˆ) stands for the bootstrapping
based SE. The coverage probabilities associated with the method κv,tr are fairly close to the
nominal 95% level, dipping to 93% in a few cases. The methods, κ and κv, have similar and
generally more conservative performance in terms of the empirical coverage probabilities. Note
that the results presented for these two methods are only based on simulations which produce
converged estimates. In Scenario 2 where the convergence rates of κ and κv can be considerably
below 1, the results in Figure 1 may over-represent the performance of these two methods.
Based on all the simulations, the method κv,tr evidences the best performance of the different
weighting methods, exhibiting good coverage probabilities, low bias, and reliable convergence.
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4 Colon Cancer Screening with Flexible Sigmoidoscopy
Colorectal cancer initiates in the colon or rectum (parts of the large intestine). It is the third
most common cause of cancer deaths for both men and women in the United States (Siegel et al.).
Screening has been suggested for early detection of colon cancer and precancerous lesions known
as polyps, with the ultimate goal of reducing colon cancer deaths. There are several recommended
screening protocols, including fecal occult blood test (FOBT), fecal immunochemical test (FIT),
colonoscopy, virtual colonoscopy and flexible sigmoidoscopy.
The Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial is a multi-
center, two-armed randomized trial, sponsored by the National Cancer Institute, of screening
tests for prostate, lung, colorectal and ovarian cancers. Ten centers across the U.S. recruited
approximately 155,000 participants between November 1993 and July 2001. Data were collected
until December 31, 2009. One objective of the trial is evaluating the effectiveness of screening
with flexible sigmoidoscopy on mortality from colorectal cancer compared to usual-care. Prorok
et al. (2000) reported further details about this trial.
The original data consist of 154,897 individuals aged 55 to 74 years. They were randomly
assigned to either the usual-care (control, N = 77,453) group or the screening with flexible
sigmoidoscopy (intervention, N = 77,444) group. For the intervention group, subjects were
offered the screening at baseline and 3 or 5 years later. The data from 187 participants who
dropped out, died, were diagnosed with cancer, or had an organ removed before the first screening
visit and the data on 4 participants who have no follow-up after randomization are discarded.
Thus, we only consider 154,706 individuals in our analyses.
Table 2 presents descriptive statistics for the baseline characteristics of the participants strat-
ified by the screening assignment (i.e. V = 0, V = 1) and the actual screening status (i.e. D = 0,
D = 1). We also consider risk factors, including age (in years), gender, family history of any
cancer, family history of colorectal cancer, colorectal polyps, and diabetes. We apply t-tests or
chi-square tests to check the balance of these observed risk factors between the groups deter-
mined by the screen assignment or the actual screening status. Based on the p-values reported in
Table 2, there is strong evidence that this trial was well randomized, with small and nonsignifi-
cant associations between the screening assignment and the risk factors. However, most of these
risk factors are unbalanced by the actual screening status. The summary statistics in Table 2
suggest that participants, who were older, male, with family history of any cancer or with family
history of colorectal cancer, or with diabetes, were more likely to take the colon cancer screening
when it was assigned. Thus, there is some evidence to suggest that the study participants’ post-
randomization care selections and their potential survival outcomes are dependent. Hence, the
traditional ITT or the “as-treated” analysis may be problematic for evaluating the causal effect
of flexible sigmoidoscopy screening on colorectal cancer mortality.
To address this issue, we employ the proposed IV methods, with the survival outcome of
interest (T ) defined as the time from trial entry (i.e. randomization) to death from colorectal
cancer (in years), and the IV chosen as the screening assignment (V ). In our dataset, 351 and
249 colorectal cancer deaths were observed in the control group (n = 77098) and the intervention
group (n = 77,098) respectively; 409 and 191 colorectal cancer deaths were observed in the group
without screening (n = 89,647) and the group with screening (n = 64,459) respectively. In our
analysis, deaths due to other causes are competing risks for death from colon cancer. As discussed
in Section 2.6, naively treating such competing events as censoring events leads to a valid IV
proportional hazards analysis of the cause-specific hazard function for colon cancer death. Our
instrumental variable is justified as follows: (i) the screening assignment is highly informative
of the actual screening status (D) (i.e. screened vs. not screened); (ii) the screen assignment is
random and hence is expected to be independent of unmeasured confounders (given the observed
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Table 2: Characteristics of the Study Participants
Characteristics Control (V = 0) Intervention (V = 1) Not Screened (D = 0) Screened (D = 1)
N = 77449 N = 77257 N = 90056 N = 64650
Number of Participants (%) p-value Number of Participants (%) p-value
Age ⋆
62.60 (5.37) 62.59 (5.39) 0.8274 62.65 (5.39) 62.52 (5.33) <.0001
Age Level
55-59 yr 25838 (33.36) 25789 (33.38) 29902 (33.20) 21725 (33.60)
60-64 yr 23767 (30.69) 23736 (30.72) 27451 (30.48) 20052 (31.02)
65-69 yr 17473 (22.56) 17402 (22.52) 20352 (22.60) 14523 (22.46)
70-74 yr 10371 (13.39) 10330 (13.37) 0.9967 12351 (13.71) 8350 (12.92) <.0001
Sex
Male 38340 (49.50) 38229 (49.48) 43529 (48.34) 33040 (51.11)
Female 39109 (50.50) 39028 (50.52) 0.9393 46527 (51.66) 31610 (48.89) <.0001
Family History of Any Cancer
No 32742 (42.28) 33327 (43.14) 37798 (41.97) 28271 (43.73)
Yes 41305 (53.33) 41971 (54.33) 0.8735§ 47137 (52.34) 36139 (55.90) 0.0190§
Unknown 3402 (4.39) 1959 (2.54) <.0001 5121 (5.69) 240 (0.37) <.0001
Family History of Colorectal Cancer
No 64504 (83.29) 65203 (84.40) 73997 (82.17) 55710 (86.17)
Yes † 7320 (9.45) 7627 (9.87) 0.0809§ 8331 (9.25) 6616 (10.23) 0.0022§
Possibly ‡/Unkown 5625 (7.26) 4427 (5.73) <.0001 7728 (8.58) 2324 (3.59) <.0001
Colorectal Polyps
No 68690 (88.69) 69910 (90.49) 78705 (87.40) 59895 (92.65)
Yes 4947 (6.39) 5185 (6.71) 0.1565§ 5739 (6.37) 4393 (6.80) 0.7865§
Unknown 3812 (4.92) 2162 (2.80) <.0001 5612 (6.23) 362 (0.56) <.0001
Diabetes
No 68028 (87.84) 69371 (89.79) 77773 (86.36) 59626 (92.23)
Yes 5699 (7.36) 5810 (7.52) 0.9971§ 6776 (7.52) 4733 (7.32) <.0001§
Unknown 3722 (4.81) 2076 (2.69) <.0001 5507 (6.12) 291 (0.45) <.0001⋆ denotes a continuous variable. Mean and standard deviation are reported.
† indicates colorectal cancer family history in immediate family member.
‡ indicates colorectal cancer family history in relatives or unclear cancer type.
§ indicates p-value without considering missing category.
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risk factors); (iii) it is reasonable to expect that the impact of the screening assignment on the
survival outcome is only through its influence on the actual screening status.
It is worth noting that this study assumes that individuals who were assigned usual care did
not have access to other colorectal screening programs (i.e. P (D0 = 0∣X) = 1). This renders a
special case of perfect exclusion of the control and treatment groups (Abadie, 2003), where the
assumption (A4) holds trivially. In this case, we have
λ(T ∣D1 >D0,X,D = 1) = λ(T1∣D1 = 1,X, V = 1) = λ(T1∣D = 1,X)
and
λ(T ∣D1 >D0,X,D = 0) = λ(T0∣D1 = 1,X, V = 0)= λ(T0∣D1 = 1,X, V = 1) = λ(T0∣D = 1,X).
Thus, βd in our IV analyses can be interpreted as the causal effect of the flexible sigmoidoscopy
screening for screened participants given observed risk factors.
We first assess the unadjusted causal effect of the flexible sigmoidoscopy screening by fitting
model (1) without X to the full dataset and stratifying the analysis by each risk factor. For
comparison purposes, we also perform the “as-treated” counterparts (i.e. fitting a Cox model
for T with D being the only covariate), and the ITT counterparts (i.e. fitting a Cox model for
T with V being the only covariate) of these IV analyses. For the IV analyses, we implement
the three methods κ, κv, and κv,tr in the same way as in our simulation studies (see Section
3), except we use a simple logistic regression model stratified by (δ,D) to estimate the v0(U) in
(10). Table 3 reports the parameter estimates and the associated standard errors. For the IV
methods, we present the bootstrap-based standard errors.
Table 3 also reports the rate of compliance in the intervention group (i.e. the proportion of
screened participants in the intervention group), pc.
From Table 3, we observe that the estimates for the causal effect of screening are very similar
among the three IV methods. The conclusions regarding the survival impact of screening are
generally consistent across the IV analyses, the as-treated analyses, and the ITT analyses, except
for the sub-cohort with baseline age between 70 and 74 years and the sub-cohort with diabetes.
In these two cases, rather large, significant benefits of screening are suggested by the as-treated
analyses but not by the ITT or IV analyses. Such discrepancies may be explained by the relatively
high noncompliance rates (≈ 19%) observed in the intervention group. That is, study participants
who refused assigned screening are likely to be less health-conscious, which may be associated
with worse potential survival outcomes. When the non-screened group includes a large proportion
of such participants, the as-treated analyses would tend to over-estimate the benefit of screening
as a result of ignoring the survival impact of the unmeasured confounder related to health-
consciousness. Therefore, in these two cases, it is more plausible to conclude that the flexible
sigmoidoscopy screening offers little survival benefits for the participants aged between 70 and
74 years and for participants with diabetes. Overall, the unadjusted stratified analyses support
the benefit of flexible sigmoidoscopy in reducing colorectal mortality, with the greatest benefit
in subpopulations with relatively low mortality risk, for example, age group 55-59 years and
subjects without family history of colorectal cancer.
We next evaluate the causal effect of screening while accounting for other risk factors. Specif-
ically, we fit model (1) with X capturing gender, family history of any cancer, family history
of colorectal cancer, colorectal polyps, and diabetes, separately for the four age groups, 55-59
years, 60-64 years, 65-69 years, and 70-74 years. Table 4 provides the summary statistics (i.e.
count and percentage) of the risk factors by V and by D within each age group, along with the
p values from testing the association of the risk factors with V or D based on the Chi-square
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Table 3: Analyses for the Unadjusted Screening Effect Based on the Whole Data Set or Stratified
by Each Risk Factor
Data N pc As-Treated ITT κ κv κv,tr
(Subgroup) Parameter Estimates (Standard Errors)
Total 154706 0.84 -0.442* -0.343* -0.427* -0.427* -0.427*
(0.088) (0.083) (0.099) (0.097) (0.101)
Age Level
55-59 yr 51627 0.84 -0.572* -0.380* -0.496* -0.496* -0.496*
(0.198) (0.184) (0.229) (0.240) (0.248)
60-64 yr 47503 0.84 -0.313 -0.130 -0.169 -0.169 -0.169
(0.160) (0.153) (0.201) (0.198) (0.193)
65-69 yr 34875 0.83 -0.475* -0.590* -0.654* -0.655* -0.655*
(0.164) (0.158) (0.178) (0.164) (0.182)
70-74 yr 20701 0.81 -0.420* -0.264 -0.351 -0.350 -0.350
(0.188) (0.176) (0.228) (0.213) (0.218)
Sex
Male 76569 0.86 -0.549* -0.445* -0.536* -0.536* -0.536*
(0.115) (0.109) (0.124) (0.123) (0.123)
Female 78137 0.81 -0.319* -0.200 -0.262 -0.262 -0.262
(0.135) (0.128) (0.156) (0.172) (0.166)
Family History of Any Cancer
Yes 83276 0.86 -0.237* -0.258* -0.294* -0.294* -0.294*
(0.114) (0.111) (0.120) (0.124) (0.127)
No 66069 0.85 -0.704* -0.492* -0.639* -0.639* -0.639*
(0.144) (0.132) (0.158) (0.179) (0.162)
Family History of Colorectal Cancer
Yes 14947 0.87 -0.010 -0.097 -0.105 -0.106 -0.106
(0.241) (0.239) (0.251) (0.271) (0.254)
No 129707 0.85 -0.457* -0.391* -0.469* -0.469* -0.469*
(0.099) (0.094) (0.117) (0.113) (0.104)
Colorectal Polyps
Yes 10132 0.85 0.315 0.288 0.335 0.336 0.336
(0.305) (0.309) (0.388) (0.405) (0.389)
No 138600 0.86 -0.490* -0.401* -0.490* -0.485* -0.485*
(0.093) (0.089) (0.111) (0.112) (0.110)
Diabetes
Yes 11509 0.81 -1.036* -0.335 -0.606 -0.603 -0.603
(0.311) (0.253) (0.451) (0.454) (0.438)
No 137399 0.86 -0.355* -0.349* -0.404* -0.404* -0.404*
(0.093) (0.090) (0.095) (0.099) (0.092)
* indicates p-value ≤ 0.05
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Table 5: Results of Adjusted Models within Age Subgroups
Age Level As-Treated ITT κ κv κv,tr
(pc) Covariates Point Estimates (Standard Errors)
55-59 yr Screening -0.474* (0.207) -0.296 (0.196) -0.373 (0.228) -0.373 (0.242) -0.373 (0.246)
(0.84) Female -0.101 (0.195) -0.089 (0.195) -0.003 (0.244) -0.013 (0.246) -0.013 (0.232)
Family History of Any Cancer 0.204 (0.208) 0.201 (0.208) 0.468 (0.272) 0.463 (0.280) 0.465 (0.280)
Family History of Colorectal Cancer 0.194 (0.313) 0.192 (0.313) -0.080 (0.471) -0.071 (0.468) -0.073 (0.386)
Colorectal Polyps 0.276 (0.422) 0.277 (0.422) 0.137 (0.736) 0.135 (1.725) 0.131 (1.768)
Diabetes 0.168 (0.392) 0.179 (0.392) 0.127 (0.606) 0.125 (0.591) 0.126 (0.710)
60-64 yr Screening -0.333* (0.169) -0.184 (0.163) -0.228 (0.197) -0.229 (0.205) -0.242 (0.181)
(0.84) Female -0.419* (0.167) -0.409* (0.166) -0.579* (0.214) -0.585* (0.206) -0.563* (0.189)
Family History of Any Cancer -0.182 (0.176) -0.183 (0.176) -0.055 (0.234) -0.054 (0.231) -0.071 (0.225)
Family History of Colorectal Cancer 0.396 (0.260) 0.391 (0.260) 0.564* (0.279) 0.566* (0.275) 0.556* (0.276)
Colorectal Polyps -0.124 (0.329) -0.121 (0.329) -0.141 (0.429) -0.147 (0.446) -0.108 (0.351)
Diabetes 0.520* (0.258) 0.526* (0.258) 0.114 (0.458) 0.117 (0.554) 0.206 (0.369)
65-69 yr Screening -0.386* (0.168) -0.526* (0.165) -0.564* (0.187) -0.568* (0.166) -0.576* (0.188)
(0.83) Female -0.402* (0.164) -0.388* (0.164) -0.426* (0.194) -0.435* (0.181) -0.408* (0.182)
Family History of Any Cancer -0.182 (0.176) -0.185 (0.176) -0.187 (0.190) -0.190 (0.196) -0.198 (0.186)
Family History of Colorectal Cancer 0.565* (0.129) 0.563* (0.139) 0.625* (0.260) 0.642* (0.242) 0.627* (0.253)
Colorectal Polyps -0.306 (0.314) -0.299 (0.314) -0.226 (0.331) -0.243 (0.349) -0.245 (0.328)
Diabetes 0.370 (0.251) 0.377 (0.251) 0.036 (0.419) 0.045 (0.411) 0.138 (0.313)
70-74 yr Screening -0.414* (0.196) -0.364 (0.186) -0.437 (0.225) -0.439* (0.223) -0.439* (0.223)
(0.81) Female -0.486* (0.189) -0.467* (0.189) -0.472* (0.228) -0.484* (0.246) -0.486* (0.228)
Family History of Any Cancer 0.157 (0.195) 0.152 (0.195) 0.387 (0.250) 0.389 (0.268) 0.388 (0.233)
Family History of Colorectal Cancer -0.219 (0.318) -0.222 (0.318) -0.344 (0.508) -0.333 (0.405) -0.342 (0.384)
Colorectal Polyps 0.088 (0.286) 0.093 (0.286) 0.137 (0.387) 0.124 (0.396) 0.121 (0.349)
Diabetes 0.444 (0.270) 0.451 (0.270) -0.027 (0.583) -0.031 (0.589) -0.037 (0.409)
* indicates p-value ≤ 0.05
tests. Similarly to Table 2, within each age group, the risk factors show little association with
the screening assignment D but may be significantly different between the participants who were
screened versus those who were not screened.
Table 5 presents the parameter estimates and the associated standard errors based on the
IV methods, κ, κv, and κv,tr. The coefficient estimates from the as-treated analysis (i.e. a
multivariate Cox model for T given D and X) and the ITT analysis (i.e. a multivariate Cox
model for T given V and X) are also presented along with the corresponding standard errors.
From Table 5, we again observe a quite good agreement among the three IV estimates. The IV
analyses suggest that the flexible sigmoidoscopy screening has a significant protective effect on
colorectal cancer mortality in the older age groups, such as 65-69 years and 70-74 years, but not
in the younger age groups, 55-59 years and 60-64 years, after adjusting for age, gender, family
history of any cancer, family history of colorectal cancer, and colorectal polyps, and diabetes.
This finding is generally consistent with that based on the ITT analyses, but moderately disagrees
with the results from the as-treated analyses, particularly in the age groups, 55-59 years and 60-
64 years. In these two age groups, we observe a more marked imbalance of risk factors by the
actual screening status, compared to that presented in the two older age groups. For example, in
the age group 60-64 years, participants who were female, had diabetes, or had no family history of
colorectal cancer are significantly less likely to comply to the assigned screening assignment than
those who were males, had no diabetes, or had a family of colorectal cancer. Such associations
may bias the estimation of the causal treatment effect by the as-treated analyses, and this may
explain the discrepancies observed in Table 5 between the as-treated analyses and the IV analyses.
In addition, the IV analyses provide strong evidence for the lower colorectal cancer mortality
risk in females (versus males) in all age groups beyond the age of 60 years. They also suggest
some survival disadvantages (regarding colorectal cancer mortality) associated with the presence
of family history of colorectal cancer.
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5 Concluding Remarks
The use of instrumental variables in survival settings with binary treatments has been severely
limited by complexities arising from nonlinear model specifications, as with the proportional
hazards model. The application of simple two stage estimation procedures developed for linear
models is challenging and only valid in special cases. Alternative procedures may entail strong
modelling assumptions on strata other than that of interest, tend to be complex, both com-
putationally and inferentially, and are not readily implemented using standard software. Our
approach based on a special characterization of instrumental variables enables a simple two stage
procedure analogous to propensity score weighting. At the first stage, a binary regression model
is fit to the instrumental variable while at the second stage, the fitted regression model from the
first stage is used to construct a weight which “debiases” naive estimating equation for the pro-
portional hazards model. Previous work on this approach (Abadie et al., 2002; Abadie, 2003) has
only considered iid estimating equations with limited attention to the practical computational
issues. The current paper demonstrates rigorously its validity with the partial likelihood score
function. Moreover, the proposed estimators can be easily computed using existing software
for the proportional hazards model, with variance estimation based on bootstrapping correctly
accounting for the first stage estimation of the weights.
As shown in Section 2.6, the weighting approach is generally applicable to instrumental vari-
able estimation of proportional hazards model in complex survival scenarios, for example, in
the presence of left truncation, competing risks, and recurrent events. The developed weighting
technique may be applied to other survival regression models with binary treatment and binary
instrumental variable. Application to the quantile regression model, the accelerated lifetime
model, the additive hazard model, and transformation models are currently under investigation
with right censored survival data. The main requirement is the existence of an unbiased esti-
mating equation in the absence of unmeasured confounding. Such estimating equations can be
incorporated into the second stage of the two stage procedure described in this paper for the
proportional hazards model.
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A Justifications for κv
Recall U = (W,δ,D,X). It is easy to see that
E(D(1 − V )∣U) = P (D(1 − V ) = 1∣U) = P (D1 =D0 = 1∣U)P (V = 0∣D1 =D0 = 1,U)= P (D1 =D0 = 1∣U)P (V = 0∣D1 =D0 = 1,W1 =min(T1,C), δ1 = I(T1 ≤ C),X)= P (D1 =D0 = 1∣U)P (V = 0∣X).
The last equality uses the aforementioned assumption that censoring is independent of the instru-
mental variable V conditional on X and the assumption of joint independence of (D1,D0, T1, T0)
and V conditional on X.
Similarly, E((1 −D)V ∣U) = P (D1 =D0 = 0∣U)P (V = 1∣X). It then follows that
κv = E {1 − D(1 − V )
P (V = 0∣X) − (1 −D)VP (V = 1∣X) ∣U}= 1 − P (D1 =D0 = 1∣U) − P (D1 =D0 = 0∣U) = P (D1 >D0∣U).
The result above indicates that κv is always nonnegative. The justification for using the
projected weight E(κ∣U) follows from the arguments in Abadie et al. (2002)
B Proofs of Theorem 1 and Theorem 2
Proof of Theorem 1: Define φ(α,O) ≡ 1− D(1−V )
1−ψ(α,X) − (1−D)Vψ(α,X) , and Qn(α,β) = n−1/2Un,φ(α,O)(β).
Then Qn(α0,β) = n−1/2Un,κ(β) and Qn(αˆ,β) = n−1/2Un,κˆ(β). Under conditions (C1)-(C3),
we have ∥∂Qn(α,β)/∂α∥ is bounded in a neighborhood of α = α0. Given αˆ is a consistent
estimator of α0 (i.e condition (C5)), applying Taylor expansion to Qn(αˆ,β) around α = α0
implies that
sup
β∈B ∥n−1/2{Un,κˆ(β) −Un,κ(β)}∥→a.s. 0. (14)
By the Glivenko-Cantelli Theorem (van der Vaart and Wellner, 1996), we can show under
conditions (C1)-(C2) that
sup
β∈B,t ∥n−1S(j)n,κ(β, t) − s(j)c (β, t)∥→a.s. 0, j = 0,1.
Given condition (C3), this implies supβ∈B,t ∥En,κ(β, t) − ec(β, t)∥→a.s. 0. Then,
sup
β∈B ∥Un,κ(β) − U¯n,κ(β)∥ ≤ n−1/2 n∑i=1∫ ∞0 ∥En,κ(β, s) − ec(β, s)∥dMi(s)≤ sup
β∈B,t ∥En,κ(β, t) − ec(β, t)∥ ⋅ {n−1/2 n∑i=1∫ ∞0 dMi(s)} = o(1), a.s. (15)
By the results in Abadie (2003) and an application of the Glivenko-Cantelli Theorem (van der
Vaart and Wellner, 1996), we get
sup
β∈B ∥U¯n,κ(β) −µc(β)∥ = o(1), a.s. (16)
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It follows from (14),(15), and (16) that
sup
β∈B ∥n−1/2Un,κˆ(β) −µc(β)∥ = o(1), a.s. (17)
By condition (C4), µc(β) is a concave function with a unique maximizer β = β0. Suppose
βˆ does not converge to β0, a.s. Then P (E) > 0, where E={∃ a subsequence nk such that
βˆnk → β∗ ≠ β0}. By the definition of βˆ, we have n−1/2Un,κˆ(βˆnk) ≥ n−1/2Un,κˆ(β0) in E , which
implies µc(β∗) ≥ µc(β0) given (17). This contradicts the fact that β0 is the unique maximizer
of µc(β). Therefore, we have βˆ →a.s. β0.
Proof of Theorem 2: Define Ai(β) = ∫ ∞0 κi{Zi − En,κ(β, s)}dNi(s), Aˆi(β) = ∫ ∞0 κˆi{Zi −
En,κˆ(β, s)}dNi(s). Then
0 = Un,κˆ(βˆ) = Un,κ(βˆ) + n−1/2 n∑
i=1{Aˆi(βˆ) −Ai(βˆ)}. (18)
Given the consistency of βˆ, the Taylor expansion of Un,κ(β) around β = β0 gives
Un,κ(βˆ) ≈ Un,κ(β0) −ϕn(β0)√n(βˆ −β0) + o(1), (19)
where ϕn(β) = 1n ∑ni=1 ∫ ∞0 κiV n,κ(β, s)dNi(s), and ≈ means the difference is o(1), a.s.
On the other hand, we can write
n−1/2 n∑
i=1{Aˆi(β) −Ai(β)} = n−1/2 n∑i=1(κˆi − κi){Zi −En,κ(β, s)}dMi(s)−n−1/2 n∑
i=1 κˆi{En,κˆ(β, s) −En,κ(β, s)}dMi(s).
Define Dφ(α,O) = ∂φ(α,O)/∂αT . Note that Dφ(α0,O) is bounded under conditions (C2).
This implies supi ∣κˆi −κi∣ = o(1), a.s. given condition (C5). By the Taylor expansion of φ(α,Oi)
around α = α0 and condition (C6), we have
n1/2(κˆi − κi) = φ(αˆ,Oi) − φ(α0,Oi) ≈Dφ(α0,Oi)n1/2(αˆ −α0)= n−1/2 n∑
j=1Dφ(α0,Oi)Iα(α0,Oj) ≡ n−1/2 n∑j=1Iκ(α0,Oj ,Oi) (20)
Given these results, we can further approximate n−1/2∑ni=1{Aˆi(β) −Ai(β)} as follows.
First, using the fact that supi ∣κˆi−κi∣ = o(1), a.s. and applying the Glivenko-Cantelli Theorem
to En,κ and En,κˆ, we get
n−1/2 n∑
i=1{Aˆi(β) −Ai(β)} ≈ n−1/2 n∑i=1(κˆi − κi){Zi − e¯(α0,β, s)}dMi(s)−n−1/2 n∑
i=1κi{e¯(αˆ,β, s) − e¯(α0,β, s)}dMi(s) ≡ (I) − (II) (21)
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where e¯(α,β, t) = s¯(1)(α,β, t)/s¯(0)(α,β, t) and s¯(j)(α,β, t) = E[φ(α,O)Y (t)Z⊗j
exp{βTZ}∣D1 >D0], j = 0,1,2.
Secondly, plugging in (20) into (I), coupled with standard manipulations, leads to
(I) = n−1/2 n∑
i=1
⎛⎝n−1 n∑j=1 [Iκ(α0,Oi,Oj)∫ ∞0 {Zj − ec(β, s)}dMj(s)]⎞⎠
≈ n−1/2 n∑
i=1IA,(I)(α0,β,Oi), (22)
where IA,(I)(α0,β,Oi) = EO [Iκ(α0,Oi,O) ∫ ∞0 {Z − ec(β, s)}dM(s)] and EO stands for ex-
pectation with respect to O.
Thirdly, assessing e¯(αˆ,β, s) − e¯(α0,β, s) through the Taylor expansion and using condition
(C6), we derive that
(II) ≈ n−1/2 n∑
i=1
⎧⎪⎪⎨⎪⎪⎩n−1
n∑
j=1∫ ∞0 φ(α0,Oj)De¯(α0,β, s)dMj(s)
⎫⎪⎪⎬⎪⎪⎭Iα(α0,Oi)≈ n−1/2 n∑
i=1IA,(II)(α0,β,Oi) (23)
where De¯(α,β, t) = ∂e¯(α,β, t)/∂α, and IA,(II)(α0,β,Oi) = EO{∫ ∞0 φ(α0,O)De¯(α0,β, s)
dM(s)} ⋅Iα(α0,Oi).
Define IA(α,β,Oi) = IA,(I)(α,β,Oi)−IA,(II)(α,β,Oi) and ai(β) = ∫ ∞0 κi {Zi − ec(β, s)}
dMi(s). It follows from (18), (19), (21), (22), and (23) that
n1/2(βˆ −β0) ≈ {ϕn(β0)}−1{U¯n,κ(β0) + n−1/2 n∑
i=1IA(α0,β0,Oi)}= n−1/2 n∑
i=1{ϕn(β0)}−1{ai(β0) + IA(α0,β0,Oi)}
By the Central Limit Theory, we have
n1/2(βˆ −β0)→d N(0,Ω),
where
Ω = E([{ϕn(β0)}−1{ai(β0) + IA(α0,β0,O)}]⊗2). (24)
C Supplemental Figures and Tables
Below we provide two figures showing the objective function and estimating function surfaces
for the three proposed estimators. These were selected to demonstrate the numerical issues
present in the approach and why convergence sometimes fails, and the benefits of the modified
and truncated weight κˆv,tr. The figures also demonstrate why we prefer to utilize the objective
function over the estimating equation.
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Figure 3: Non-converged dataset from simulation 2 case 1. The left column
shows the objective function for κ, κv, κv,tr, respectively. The right column
shows the estimating function plots for methods, κ, κv, κv,tr, respectively
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Figure 4: Dataset from scenario 2 case 1 with converged estimate. The left
column shows the objective function for κ, κv, κv,tr, respectively. The right
column shows the estimating function plots for κ, κv, κv,tr, respectively
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